Impact of COVID-19 on lung cancer care in New South Wales, Australia: real-world data from the EnRICH Program

被引:0
|
作者
Brown, Bea [1 ]
Young, Jane [2 ]
Galpin, Kirsty [3 ]
Boyer, Michael [4 ]
Chin, Venessa [5 ,6 ]
Brown, Chris [1 ]
Simes, Robert J. [1 ]
机构
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia
[3] Univ Sydney, Sch Psychol, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW, Australia
[4] Chris OBrien Lifehouse, Sydney, NSW, Australia
[5] St Vincents Hosp, Sydney, NSW, Australia
[6] Garvan Inst Med Res, Sydney, NSW, Australia
来源
PUBLIC HEALTH RESEARCH & PRACTICE | 2024年 / 34卷 / 03期
关键词
UK;
D O I
10.17061/phrp3432423
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: The coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare systems worldwide, causing substantial changes to routine healthcare delivery. National and international modelling studies have predicted adverse impacts of this disruption. This study aimed to assess the real-world impact of the COVID-19 pandemic on quality of care and outcomes for patients with lung cancer in New South Wales (NSW). Study type: Pre-post observational cohort study using data prospectively collected for the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program. Methods: The study population comprised 2000 patients with lung cancer from six specialist cancer centres in metropolitan and regional NSW. We split this population into two cohorts: the pre-COVID-19 cohort (1143 patients diagnosed from 8 September 2016 to 10 March 2020) and the post-COVID-19 cohort (857 patients diagnosed from 11 March 2020 to 28 October 2021). The main outcome measures were lung cancer clinical quality indicators, 1-year and 2-year overall survival, and patient-reported health-related quality of life and psychological distress. Results: Patient and disease characteristics (e.g. age, gender, cancer stage) were similar for the pre-and post-COVID-19 cohorts, except for histology (non- small cell lung cancer (NSCLC) 88% in the pre-COVID-19 cohort and 84% in the post-COVID-19 cohort; p = 0.008) and region of residence (62% and 55%, respectively, lived in metropolitan areas; p = 0.002). Compared to the pre-COVID-19 cohort, fewer patients in the post-COVID-19 cohort received a diagnosis within 28 days of the first investigation of symptoms (clinical diagnosis: 77% compared with 72%; p = 0.017, pathological diagnosis: 60% compared with 53%; p = 0.005). However, the median time from the first investigation of symptoms to treatment initiation did not differ. One- and 2-year overall survival, quality of life and psychological distress did not differ between cohorts. Conclusions: This analysis found that the COVID-19 pandemic did not significantly adversely affect quality of care and outcomes for patients with lung cancer in NSW. Reassuringly, these results suggest that prioritising urgent health services, such as cancer care and implementing protective mitigation measures were effective in avoiding the predicted adverse outcomes of healthcare service disruption.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] IMPACT OF COVID-19 AMONG MYASTHENIA GRAVIS PATIENTS: A CERNER REAL-WORLD™ DATA STUDY
    Digala, Lakshmi
    Prasanna, Shivika
    Rao, Praveen
    Qureshi, Adnan
    Govindarajan, Raghav
    MUSCLE & NERVE, 2021, 64 : S9 - S9
  • [22] Real-world impact of the COVID-19 pandemic on the assessment of anaesthesiology residents
    Kealey, Alayne
    Alam, Fahad
    McCreath, Graham
    Matava, Clyde T.
    Bahrey, Lisa A.
    Walsh, Catharine M.
    BRITISH JOURNAL OF ANAESTHESIA, 2020, 125 (05) : E430 - E432
  • [23] Evaluating real-world data in COVID-19 antigen and PCR testing
    Rose, Olaf
    Obarcanin, Emina
    Erzkamp, Susanne
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2023, 61 (04) : 172 - 177
  • [24] COVID-19 real-world data for the US and lessons to reopen business
    Goldschmidt-Clermont, Pascal J.
    PLOS PATHOGENS, 2020, 16 (08)
  • [25] COVID-19 confidential: Enabling trust in COVID-19 research with fit for purpose real-world data
    Gatto, Nicolle M.
    Franklin, Jessica
    Garry, Elizabeth M.
    Martin, David
    Chakravarty, Aloka
    Rassen, Jeremy A.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 6 - 6
  • [26] New approaches to cancer care in a COVID-19 world
    Butler, John
    Finley, Christian
    Norell, Charles H.
    Harrison, Samantha
    Bryant, Heather
    Achiam, Michael P.
    Altman, Alon D.
    Baxter, Nancy
    Bentley, James
    Cohen, Paul A.
    Chaudry, M. Asif
    Dixon, Elijah
    Farrell, Rhonda
    Fegan, Scott
    Hashmi, Salila
    Hogdall, Claus
    Jenkins, John T.
    Kwon, Janice
    Mala, Tom
    McNally, Orla
    Merrett, Neil
    Nelson, Gregg
    Nordin, Andy
    Park, Jason
    Porter, Geoff
    Reynolds, John
    Schieman, Colin
    Schnack, Tine
    Spigelman, Allan
    Svendsen, Lars Bo
    Sykes, Peter
    Thomas, Robert
    LANCET ONCOLOGY, 2020, 21 (07): : E339 - E340
  • [27] The Impact of COVID-19 for Social Work in the Intensive Care Unit, Westmead Hospital, New South Wales
    Vo, Christine
    AUSTRALIAN SOCIAL WORK, 2021, 74 (01) : 125 - 126
  • [28] Cancer patients infected with COVID-19 at La Princesa Hospital: Real-world data study
    Toquero Diez, P.
    Vera Cea, B.
    Garrido Garcia, A.
    Mendez Carrascosa, E. R.
    Banon Torres, D.
    Colomer Bosch, R.
    Romero Laorden, N.
    Hernandez, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1023 - S1023
  • [29] Impact of COVID-19 on Medical Care Conduct and Psychological Burden Among Patients With Psoriasis: Real-World Data From a Tertiary Hospital in China
    Zhang Ying
    Guo Jin-Zhu
    Zhang Chun-Lei
    国际皮肤性病学杂志(英文), 2023, 06 (02)
  • [30] Effectiveness evaluation of digital contact tracing for COVID-19 in New South Wales, Australia
    Vogt, Florian
    Haire, Bridget
    Selvey, Linda
    Katelaris, Anthea L.
    Kaldor, John
    LANCET PUBLIC HEALTH, 2022, 7 (03): : E250 - E258